Levobupivacaine
CAS: 27262-47-1
Ref. TM-T1787
5mg | 52,00 € | ||
10mg | 67,00 € | ||
25mg | 96,00 € | ||
50mg | 138,00 € | ||
100mg | 190,00 € | ||
200mg | 278,00 € | ||
500mg | 476,00 € | ||
1ml*10 (DMSO) | 49,00 € |
Información del producto
- (-)-(S)-Bupivacaine
- (-)-Bupivacaine
- (2S)-1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
- (2S)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
- 2',6'-Pipecoloxylidide, 1-butyl-, (-)-
- 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)-
- 2′,6′-Pipecoloxylidide, 1-butyl-, (-)-
- <span class="text-smallcaps">L</span>-(-)-Bupivacaine
- Chirocain
- L-(-)-Bupivacaine
- Ver más sinónimos
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.
Propiedades químicas
Consulta técnica sobre: TM-T1787 Levobupivacaine
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.